Comparative Study
doi: 10.1136/dtb.2012.06.0115.
Exenatide for once-weekly administration
- PMID: 22789767
- DOI: 10.1136/dtb.2012.06.0115
Item in Clipboard
Comparative Study
Exenatide for once-weekly administration
Drug Ther Bull.
2012 Jul.
Abstract
▾Exenatide is a glucagon-like peptide 1 (GLP-1) agonist used in the management of people with type 2 diabetes. A twice-daily injectable formulation (▾Byetta - Eli Lilly) was licensed in 2006. ▾Bydureon (Eli Lilly) is a prolonged-release injectable formulation that allows once-weekly administration. Here we discuss the place of Bydureon in the management of type 2 diabetes mellitus.
Similar articles
-
Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.Ann Pharmacother. 2012 Jan;46(1):68-78. doi: 10.1345/aph.1Q379. Ann Pharmacother. 2012. PMID: 22232377 Review.
-
Exenatide once weekly in type 2 diabetes mellitus.Expert Opin Pharmacother. 2011 Jun;12(8):1297-1303. doi: 10.1517/14656566.2011.573145. Expert Opin Pharmacother. 2011. PMID: 21548720 No abstract available.
-
Once-weekly exenatide: an extended-duration glucagon-like peptide agonist for the treatment of type 2 diabetes mellitus.Pharmacotherapy. 2013 Jun;33(6):627-38. doi: 10.1002/phar.1240. Epub 2013 Apr 1. Pharmacotherapy. 2013. PMID: 23553357 Review.
-
Clinical effects of once-weekly exenatide for the treatment of type 2 diabetes mellitus.Am J Health Syst Pharm. 2013 Jul 1;70(13):1123-31. doi: 10.2146/ajhp120168. Am J Health Syst Pharm. 2013. PMID: 23784159 Review.
-
Extended-release exenatide (Bydureon) for type 2 diabetes.Med Lett Drugs Ther. 2012 Mar 19;54(1386):21-3. Med Lett Drugs Ther. 2012. PMID: 22421818 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
